Stocks Merck & Co Inc

  • schering_plough_earnings.jpg

    Schering-Plough, whose shares fell earlier after its Vytorin cholesterol fighter failed another study, said its earnings fell 23 percent but beat forecasts.

  • merck_earnings.jpg

    Merck  on Monday said it was not providing long-time financial forecasts as it assesses the impact of another failed study result for its Vytorin cholesterol fighter, which it produces with Schering Plough.

  • 1) American Express reported a notable miss ($0.56 vs. expectations of $0.83), and it's not hard to see where the bulk of the miss came from. a $600 million ($374 after-tax) addition to U.S. lending credit reserves.

  • vytorin_logo.jpg

    Vytorin, a cholesterol drug marketed by drugmakers Merck and Schering-Plough, failed to meet the main goals in a new study, released Monday.

  • Stocks slipped as the morning bank rally fizzled. Merck fell following disappointing results from a cholesterol-drug study.

  • Stocks slipped as the bank rally that has stretched four sessions appeared to fizzle ahead of Wachovia's report. Merck fell following disappointing results from a cholesterol-drug study.

  • roche_logo.jpg

    The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.

  • Gains in financial stocks lifted European shares on Monday as markets cheered Bank of America's stronger-than-expected quarterly results, while declines in Roche offset some of the gains.

  • Stocks advanced, led by a fourth straight rally in bank stocks after Bank of America beat expectations. News of a potential pharma deal also gave the market a boost.

  • vytorin_logo.jpg

    Merck and Schering-Plough delayed the release of their quarterly  financial results so investors could first learn the outcome of a new study of their Vytorin cholesterol fighter, and both drug makers' shares fell on jitters about the impending trial data.

  • European stocks were set to inch higher on Monday, extending a three-session rally, as investors brace for a flurry of  corporate earnings from U.S. bellwethers such as Apple , Merck  and Bank of America.

  • Elan

    A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.

  • pfizer_hq.jpg

    Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.

  • graphic_word_ofthe_street.jpg

    The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"

  • Pharma Stocks

    One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!

  • Cramer sounds off today with viewer calls on these topics: taking a slightly more bullish look at Stryker and Zimmer Holdings , both which may have been unfairly penalized by federal investigations that are behind them now; Merck being priced lower than its worth due to negative articles about Gardasil and in his opinion is still a definite Buy; knowing when to "ring the register" and take profits when you can without fearing taxes; and one more nice healthcare Buy: Masimo, a med tech company using innovative, non-invasive technology to monitor important health indicators, like blood oxygen, carbon monoxide and hemoglobin.

  • graphic_word_ofthe_street.jpg

    The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"

  • Elan

    At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.

  • merck_logo.jpg

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • Stocks moved out of bear territory Monday as oil retreated more than $4 a barrel, easing inflation fears, and technology got a boost from two of its largest companies.